A Phase 2 interventional study of AND017 and Placebo in Renal Anemia, sponsored by Kind Pharmaceuticals LLC. Completed at 8 sites in 2 countries. Open to participants aged 20 Years to 74 Years. Per ClinicalTrials.gov, last updated 2023-10-04.
Sponsored by Kind Pharmaceuticals LLC · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 464 studies in Anemia with a site in United States — 38 open to participants now, 58 under way, 18 of them phase 3. Anemia · United States.
Among the 464 studies in Anemia with a site in United States, this one is the 163rd largest by enrollment of the 395 interventional ones that give a count, is one of 16 that started in 2021, is one of 109 in phase 2, and was the 394th registered.
1,810 studies on the registry are indexed under Anemia; 215 are open to participants now.
Browse Anemia studies →38 of the 464 studies in Anemia with a site in United States are open now. Recruiting first, the newest first:
John Mascarenhas · Sites in United States
Ages 18+
Takeda · Sites in United States, Argentina, Australia and 28 more countries
Ages 18+
Memorial Sloan Kettering Cancer Center · Sites in United States
Ages 18+
Takeda · Sites in United States, Argentina, Australia and 25 more countries
Ages 18+
Washington University School of Medicine · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 122 Anemia studies recruiting now, 67 (55%) set no upper age limit and 37 (30%) stop at 75 or younger; 34 take children under 18; 23 take healthy volunteers.
This study: 20 Years to 74 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
464 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 71 · Phase 2 136 · Phase 3 122 · Phase 4 34
First in 1992; this study’s year is marked. 16 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 113 is close to the median of 117 across 1,336 interventional studies indexed under Anemia.
Median enrollment 72 across the 395 interventional studies, 116 across the 50 observational. Of the 367 that completed or were terminated, 196 (53%) have results posted.
This tab as a report to print or save as PDF → With an account.
231 of 464 have an industry lead sponsor. The 10 most frequent:
Kind Pharmaceuticals LLC is the lead sponsor of 11 studies on the registry; 7 are open to participants now.
Kind Pharmaceuticals LLC has 6 studies filed under Anemia — fewer than ten, so there is no comparison to draw.
10 of the studies in Anemia with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06527391Phase 3University of MinnesotaCholine and Iron Deficiency | 2027-09-21 |
| NCT04747613Phase 3Novartis PharmaceuticalsLong-term Safety and Tolerability of Iptacopan in Patients With Paroxysmal Nocturnal Hemoglobinuria | 2027-10-18 |
| NCT06106269Mayo ClinicOutcomes and Quality of Life Following Rectal Artery Embolization for Bleeding Internal Hemorrhoids | 2026-12 |
| NCT05340465University of WashingtonDarbe Plus IV Iron to Decrease Transfusions While Maintaining Iron Sufficiency in Preterm Infants | 2027-01-30 |
| NCT06788691Weill Medical College of Cornell UniversityLuspatercept for Clonal Cytopenias of Uncertain Significance | 2027-02 |
Add all 10 to your calendar (.ics) → With an account.
Among the 464 studies in Anemia with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a pilot phase II study to evaluate the safety and efficacy of AND017 in NDD-CKD patients
This is a pilot phase 2, multicenter, randomized, parallel-group, double-blind, placebo-controlled, dose-ranging, safety and efficacy study of oral AND017 to treat anemia in non-dialysis-dependent chronic kidney disease patients.
Key Inclusion Criteria:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
AND017 will be administrated orally at dose A
Drug: AND017
AND017 will be administrated orally at dose B
Drug: AND017
AND017 will be administrated orally at dose C
Drug: AND017
Placebo will be administrated orally
Drug: Placebo
Orally, 3 times per week in Period 1 and randomize to TIW or QW group at the same dose in Period 2
Orally, 3 times per week
Safety Evaluations
Incidence of adverse events
Time frame: Up to 17 weeks
Rate of rise in hemoglobin for each of 3 dose levels as compared with placebo from baseline to 5 weeks after TIW oral dosing
Calculate the slope of a linear regression for each patient using all hemoglobin data collected during the Fixed-Dose Period
Time frame: Up to 5 weeks after dosing
Hb response to treatment during Period 1
Cumulative percentage of patients with Hb ≥10.0 g/dL
Time frame: Up to 5 weeks after dosing
Percentage of responder patients
Responder is defined as a hemoglobin ≥10.0 g/dL and an increase in hemoglobin by ≥1.0 g/dL
Time frame: Up to 13 weeks after dosing
Percentage of visits at which patients maintain hemoglobin between 10.0-11.0 g/dL after achieving hemoglobin ≥10.0 g/dL
Percentage of visits at which patients maintain hemoglobin between 10.0-11.0 g/dL after achieving hemoglobin ≥10.0 g/dL
Time frame: Up to 13 weeks after dosing
Change from baseline in Hb
Change from baseline in Hb
Time frame: Up to 13 weeks after dosing
Change in hemoglobin levels from baseline to the mean of weeks 10-13
Change in hemoglobin levels from baseline to the mean of weeks 10-13
Time frame: Baseline and at Week 10, 11, 12, 13, and 14
Percentage of patients who maintain hemoglobin between 10.0-11.0g/dL at each visit
Percentage of patients who maintain hemoglobin between 10.0-11.0g/dL at each visit
Time frame: Up to 13 weeks after dosing
Mean Hb levels at weeks 6-14 including the average of weeks 10-13
Mean Hb levels at weeks 6-14 including the average of weeks 10-13
Time frame: Up to 13 weeks after dosing
Cumulative incidence of lack of response over the entire treatment period
Hb level \< 10.0 g/dL and an increase in hemoglobin from baseline of \< 1 g/dL
Time frame: Up to13 weeks after dosing
To assess changes in the levels of PD indicator - EPO
To assess changes in the levels of EPO
Time frame: Baseline and at Week 2, 4, 6, 8, 10, 12, 14, and 28 days after the last dose
To assess changes in the levels of PD indicator - hepcidin
To assess changes in the levels of hepcidin
Time frame: Baseline and at Week 2, 4, 6, 8, 10, 12, 14, and 28 days after the last dose
To assess iron utilization parameter during treatment - transferrin level
To assess transferrin level during treatment
Time frame: Baseline and at Week 3, 6, 9, 12, 14, and 28 days after the last dose
To assess iron utilization parameter during treatment - total iron-binding capacity (TIBC)
To assess TIBC level during treatment
Time frame: Baseline and at Week 3, 6, 9, 12, 14, and 28 days after the last dose
To assess iron utilization parameter during treatment - transferrin saturation (TSAT)
To assess TSAT level during treatment
Time frame: Baseline and at Week 3, 6, 9, 12, 14, and 28 days after the last dose
To assess iron utilization parameters during treatment - ferritin
To assess ferritin level during treatment
Time frame: Baseline and at Week 3, 6, 9, 12, 14, and 28 days after the last dose
To assess iron utilization parameters during treatment - serum iron
To assess serum iron level during treatment
Time frame: Baseline and at Week 3, 6, 9, 12, 14, and 28 days after the last dose
Plan to share: No
No publications or documents are linked to this record.
Ran from Oct 2021 to primary completion in Jul 2023, 20 months.
Of 58 industry-sponsored phase 2 interventional studies under Anemia, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 40. This study's 20 months is below that.
Counting every sponsor, half of 88 studies reached it within 28 months; a quarter within 16 and three quarters within 56.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: AND017
Kind Pharmaceuticals LLC